BMS-986165 is named as a drug or biological intervention in 2 clinical trials in our USA and China trial registers, 2 of which are recruiting. Lead sponsors include Bristol-Myers Squibb (1) and InventisBio Co., Ltd (1). Registered phases: Phase 4 and Phase 3. Conditions studied include Systemic Lupus Erythematosus (SLE); Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE); Plaque Psoriasis.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06875960 | A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 (ClinicalTrials.gov ↗) Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) |
Phase 4 | Recruiting |
| NCT07326813 | A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis (ClinicalTrials.gov ↗) Plaque Psoriasis |
Phase 3 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Systemic Lupus Erythematosus (SLE) | 1 |
| Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) | 1 |
| Plaque Psoriasis | 1 |
| Lead sponsor | Trials |
|---|---|
| Bristol-Myers Squibb | 1 |
| InventisBio Co., Ltd | 1 |
| Register | BMS-986165 trials |
|---|---|
| Clinical trials in USA | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BMS-986165 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BMS-986165 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.